Filing summary
Entity and period: The supplied filing is BiondVax Pharmaceuticals Ltd.’s audited annual report on Form 20-F for the fiscal year ended December 31, 2018—not a Scinai Immunotherapeutics Ltd. filing or a standalone fourth-quarter filing. The financial statements are prepared under IFRS and reported in NIS; USD figures are convenience translations at NIS 3.748 per U.S. dollar.
Business context and development
BiondVax was a clinical-stage biopharmaceutical company developing M-001, a synthetic peptide-based influenza vaccine intended to provide broad, lasting protection against seasonal and pandemic strains. It had no approved products and had generated no revenue. Its pivotal Phase 3 European trial began in 2018; the first cohort enrolled 4,094 participants, and the company planned a total trial population of approximately 12,000. A U.S. NIAID-sponsored Phase 2 trial also began enrolling in 2018.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | None | None |
| Net R&D expense, after participations | NIS 71.9 million ($19.2 million) | NIS 18.8 million ($5.0 million) |
| General and administrative expense | NIS 5.2 million ($1.4 million) | NIS 4.9 million ($1.3 million) |
| Operating loss | NIS 77.1 million ($20.6 million) | NIS 23.7 million ($6.3 million) |
| Net loss | NIS 87.7 million ($23.4 million) | NIS 34.6 million ($9.2 million) |
| Net loss per share | NIS 0.34 | NIS 0.17 |
| Cash used in operating activities | NIS 57.2 million ($15.3 million) | NIS 10.1 million ($2.7 million) |
| Cash and cash equivalents at year-end | NIS 75.9 million ($20.2 million) | NIS 71.4 million ($19.0 million) |
Revenue-based margins are not meaningful because the company had no revenue. The FY 2018 R&D increase was driven principally by Phase 3 trial costs of NIS 53.7 million ($14.3 million). Capital expenditures were approximately $6.3 million, primarily for factory construction and equipment. The company reported working capital of approximately $14.7 million and an accumulated deficit of $56.3 million.
At year-end, total liabilities were NIS 137.1 million ($36.6 million), exceeding total assets of NIS 105.8 million ($28.2 million); shareholders’ equity was negative NIS 31.2 million ($8.3 million). The balance sheet included an EIB loan liability of NIS 94.4 million ($25.2 million) and government-grant liabilities of NIS 14.6 million ($3.9 million). The EIB had advanced €20 million under an interest-free facility, repayable five years after each tranche, with a first-ranking floating charge over substantially all company assets, subject to stated exclusions. The EIB also has rights to 3% of annual M-001 sales revenue under the disclosed terms.
Fourth-quarter 2018 figures are unaudited: net loss was NIS 36.5 million ($9.7 million), including net financial expense of NIS 8.5 million ($2.3 million). Fourth-quarter R&D expense was NIS 26.6 million ($7.1 million). No quarterly revenue was reported.
Changes, outlook, risks, and unusual items
- Net loss rose substantially year over year as the European Phase 3 trial and related R&D spending accelerated. Operating cash use also increased sharply.
- Cash at year-end was supported by NIS 84.3 million ($22.5 million) of EIB loan proceeds. The company said available resources would fund operations for at least 15 months; elsewhere, the financial-statement note says at least 12 months. It expected continuing losses, negative cash flow, and a need for additional financing.
- Management expected Phase 3 top-line data around the end of 2020, subject to enrollment and trial progress. The second cohort was planned for the 2019/2020 flu season, with possible enrollment adjustments or extension to another season depending on influenza incidence. The company had no U.S. Phase 3 IND and said it intended to discuss U.S. marketing approval with the FDA after successful European Phase 3 results.
- The EIB agreed after year-end to extend the facility by €4 million to €24 million, subject to conditions including enrollment in the second trial season and company funding. A draft registration statement for a contemplated rights offering was filed in March 2019; the filing does not establish its completion.
- The Jerusalem manufacturing facility had moved into use, but its production line remained under construction. The company relied on a U.S. contract manufacturer for Phase 3 supply and aimed to complete its independent line by the end of 2021, subject to trial success and resources.
- Key risks include clinical failure or delay, enrollment and influenza attack-rate uncertainty, regulatory approval and market acceptance, need for further capital, manufacturing execution, competition, and dependence on Yeda’s exclusive intellectual-property license. Israeli innovation grants carry royalty and restrictions on transferring funded technology or manufacturing outside Israel. The company also disclosed currency exposure and risks related to its Israeli operations.
- Unusual financial items include fair-value accounting for the EIB financing and government-grant liabilities, and warrant revaluation. The filing says a 2018 loan fair-value adjustment increased financial expense; reported loan principal obligations were not changed by that accounting adjustment. The EIB agreement may also require prepayment amounts designed to deliver a 20% internal rate of return upon certain specified events.
Most important facts to verify
- Confirm the issuer: this document identifies BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Reconcile the reported cash runway: management cites at least 15 months, while a financial-statement note cites at least 12 months.
- Verify the EIB loan’s contractual outstanding principal, fair-value carrying amount, repayment schedule, collateral, and conditions for the additional €4 million.
- Track Phase 3 enrollment, trial-season flexibility, safety monitoring, timing of results, and any subsequent regulatory or clinical updates.
- Check the status, funding, and timeline of the manufacturing line and the company’s dependence on its contract manufacturer.
- Review subsequent financing disclosures, including whether the contemplated rights offering was completed and its dilution impact.
- Check the financial-control disclosures: the filing’s controls section refers to evaluation dates in 2016 and 2017 despite reporting FY 2018, so the applicable assessment period is unclear from the text.